News / 

Pfizer CEO sees annual COVID vaccine rather than frequent boosters

Pfizer CEO Albert Bourla talks during a press conference after a visit to oversee the production of the Pfizer-BioNtech COVID-19 vaccine at the factory of U.S pharmaceutical company Pfizer in Puurs, Belgium, April 23, 2021.

Pfizer CEO Albert Bourla talks during a press conference after a visit to oversee the production of the Pfizer-BioNtech COVID-19 vaccine at the factory of U.S pharmaceutical company Pfizer in Puurs, Belgium, April 23, 2021. (John Thys, Pool via Reuters)


2 photos
Save Story
Leer en español

Estimated read time: 1-2 minutes

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.

JERUSALEM — Pfizer Chief Executive Albert Bourla said on Saturday that an annual COVID-19 vaccine would be preferable to more frequent booster shots in fighting the coronavirus pandemic.

Pfizer/BioNtech's COVID-19 vaccine has shown to be effective against severe disease and death caused by the heavily-mutated omicron variant but less effective in preventing transmission.

With cases soaring, some countries have expanded COVID-19 vaccine booster programs or shortened the gap between shots as governments scramble to shore up protection.

In an interview with Israel's N12 News, Bourla was asked whether he sees booster shots being administered every four to five months on a regular basis.

"This will not be a good scenario. What I'm hoping (is) that we will have a vaccine that you will have to do once a year," Bourla said.

"Once a year — it is easier to convince people to do it. It is easier for people to remember.

"So from a public health perspective, it is an ideal situation. We are looking to see if we can create a vaccine that covers omicron and doesn't forget the other variants and that could be a solution," Bourla said.

Bourla has said Pfizer could be ready to file for approval for a redesigned vaccine to fight omicron, and mass produce it, as soon as March.

Citing three studies, the U.S. Centers for Disease Control and Prevention said on Friday that a third dose of an mRNA vaccine is key to fighting omicron, providing 90% protection against hospitalization.

A preliminary study published by Israel's Sheba Medical Center on Monday found that a fourth shot increases antibodies to even higher levels than the third but was likely not enough to fend off omicron. Nonetheless, a second booster was still advised for risk groups, Sheba said.

Photos

Related stories

Most recent News stories

Related topics

CoronavirusWorldU.S.
Reuters

    STAY IN THE KNOW

    Get informative articles and interesting stories delivered to your inbox weekly. Subscribe to the KSL.com Trending 5.
    By subscribing, you acknowledge and agree to KSL.com's Terms of Use and Privacy Policy.

    KSL Weather Forecast